Oncology

Latest News

The investigators found that patients with SCLC and cachexia were more likely to have problems with treatment. | Image credit: appledesign - stock.adobe.com

Cachexia Worsens Prognosis in Older Patients With Advanced SCLC

July 9th 2025

Older patients with small cell lung cancer and significant weight loss were more likely to experience dose interruptions than patients with cachexia.

Insurance gaps | Image Credit: iQoncept-stock.adobe.com

Insurance Gaps Threaten Cancer Treatment Success

By Maggie L. Shaw

July 7th 2025

Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski

Decline in SCLC Incidence Expected to Accelerate Through 2050

By Jared Kaltwasser

June 29th 2025

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com

Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

By Kimberly Rath, PharmD

June 27th 2025

Gender rights | Image Credit: © Nadzeya-stock.adobe.com

Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care

By Maggie L. Shaw

June 23rd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

July 10th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

July 10th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

June 3rd 2014

Value Key in Oncology Care

Katie Sullivan, MA

For oncologists and other cancer care specialists, value-based care is essential.

June 3rd 2014

New Immunooncology Drug from Incyte Raises Immense Interest at ASCO

Excitement at ASCO 2014 on Incyte's new immunoonoclogy drug candidate, INCB024360 ('360),in melanoma, despite a small 'n'.

June 2nd 2014

Overdiagnosis and Overtreatment: The Cancer Paradigm

Some experts argue that overdiagnosis (OD) and overtreatment (OT) of cancer is common and increasingly costly. Others argue that current cure rates are high because of the screening processes currently in place. Both viewpoints were debated during the session "Overdiagnosis and Overtreatment in Cancer: Point/Counterpoint."

June 2nd 2014

Clinical Pathway Adherence and Barriers to Coverage

The health services research poster session held in the afternoon on the penultimate day of the 50th annual meeting of the American Society of Clinical Oncology (ASCO) presented different perspectives on issues that determine patient care decisions. This is an important discussion, especially in light of the recent report by The Wall Street Journal on WellPoint's effort to promote oncologist adherence to standardized treatment guidelines.

June 2nd 2014

The Global Perspective on Value in Cancer Care

The discussion on value in cancer care was rekindled today at the 50th annual meeting of the American Society of Clinical Oncology, but this time on a global scale. The session, "ASCO/European CanCer Organisation (ECCO) Joint Session: Value and Cancer Care," saw participation from physicians and economists from around the world, with individual perspectives on defining value and the programs being developed to address the issue.

June 1st 2014

Velcade: A Progress Report in Various Cancers

Velcade (bortezomib), developed by Millenium Pharmaceuticals, is a proteasome inhibitor that is currently approved for the treatment of multiple myeloma and relapsed mantle cell lymphoma. Several abstracts were presented at the annual meeting of the American Society of Clinical Oncology this year for its use in other indications.

June 1st 2014

Impact of the Affordable Care Act on Cancer Care

The second day at the 50th annual meeting of the American Society of Clinical Oncology ended with a session entitled "Health Care in America in 2014: Current and Future Implications of the Patient Protection and Affordable Care Act" (PPACA). The presenters provided an overview of the recent and anticipated changes related to the PPACA as well as its timeline.

June 1st 2014

The Oncologist Defines 'Value of Care'

"The Value of Cancer Care and the Professional and Ethical Obligations of the Practicing Oncologist: A Debate" delved into the ethical issues raised by the economic reality of the rising costs of cancer care for the practicing oncologist.

May 31st 2014

Encouraging Results in Leukemia from a BCL-2 Inhibitor

ABT-199, the result of a collaboration between AbbVie and Genentech, is a selective, potent, orally available BCL-2 inhibitor. The drug is being developed in collaboration by the two companies for acute myelogenous leukemia and chronic lymphocytic leukemia (CLL).

May 31st 2014

How Do You Establish Value in Cancer Care?

While the incidence of cancer continues to grow, novel and targeted therapies being developed have seen much improved survival for even the deadliest of cancers. New innovations in cancer diagnosis and treatment are associated with high cost. Cancer therapy constitutes nearly 11% of the total healthcare budget, and it is rapidly growing.

May 31st 2014

The EGF Receptor Continues to be a Promising Target in NSCLC

On the second day of the 50th annual meeting of the American Society of Clinical Oncology (ASCO), a session titled, "Targeting EGFR: the next 10 years" provided a progress report on the successful targeting of the protein in non-small cell lung cancer (NSCLC).

May 30th 2014

Insurers Use Incentives to Guide Cancer Treatment Plans

Katie Sullivan, MA

Beginning July 1, health providers can expect to receive incentives for prescribing specific cancer treatments backed by the insurance company WellPoint. The WellPoint's innovative program will pay providers $350 per patient per month each time they choose 1 of the insurer's "preferred" cancer treatment options.

May 29th 2014

New Target to Prevent Lung Metastases in Breast Cancer Patients

The research headed by Roger Gomis at IRB Barcelona, with the collaboration of Joan MassaguÃ©, describes that the loss of the suppressor RARRES3 promotes the colonization of breast cancer cells in the lung.

May 28th 2014

ASCO: Tamoxifen for 10 Years in Women with HR-Positive, Non-Metastatic Breast Cancer

The American Society of Clinical Oncology (ASCO) today issued an update to its clinical practice guideline on the use of adjuvant endocrine therapy for women with stages I-III hormone receptor positive breast cancer.

May 28th 2014

BMS Partners with Technology Company CytomX for Antibody Development Platform

BMS, which has a rapidly developing and successful immunooncology pipeline, has entered into a collaboration with CytomX to develop their Probody Therapeutics antibody platform. The Probody technology improves efficacy and safety as the antibodies are activated only in the disease microenvironment and not in normal tissue.

May 27th 2014

Ipilumumab: Potential in the Treatment of Advanced Prostate Cancer

An international study carried out with involvement of the MedUni Vienna is giving hope to patients with advanced prostate cancer. In just a few years' time, Ipilumumab could be approved as a treatment for the world's third-most common type of cancer.

May 27th 2014

Aurora A Kinase Inhibitor Shows Promise in Phase I for NHL and CLL

A new chemotherapy drug (alisertib or MLN8237) being investigated for its potency against two types of cancer was found by scientists to be effective in about one-third of the 58 patients who participated in a phase I study.

May 27th 2014

Panitumumab-with FOLFOX Approved for mCRC Patients with WT KRas

Vectibix is the First and Only Biologic to Offer Significant Survival Benefit as a First-Line Treatment with FOLFOX Chemotherapy for Patients with Wild-Type KRAS Metastatic Colorectal Cancer Approval Reinforces Amgen Commitment to Personalized Medicine.

May 23rd 2014

Blocking Autophagy With Anti-Malarial Drug Finds Clinical Success

Trials conducted at the Abramson Cancer Center among others have identified the potential of an antimalarial agent, hydroxychloroquine, in stabilizing aggressive cancers.

May 23rd 2014

Roche's Gazyvaro Receives Backing of EU's CHMP for CLL

EU's Committee for Medicinal Products for Human Use (CHMP)supported the use of Gazyvaro based on the phase III CLL11 study, wherein treatment with Gazyvaro (obinutuzumab) plus chlorambucil significantly reduced the risk of disease worsening or death by 86% and increased survival time for previously untreated CLL patients compared to those who received treatment with chlorambucil alone.

May 22nd 2014

A Novel Target for Treating HER2-Positive Breast Cancer

Scientists at Cold Spring Harbor Laboratory (CSHL) today report a discovery that they hope will lead to the development of a powerful new way of treating an aggressive form of breast cancer.

May 22nd 2014

c-Met Signals to Intracellular Rac to Promote Breast Cancer Metastasis

A research article published in Nature Communications identifies a new mechanism of breast cancer metastasis.

May 21st 2014

Encouraging Results With Vaccine Against Pancreatic Cancer Developed at CINJ

'Encouraging' Period of Stable Disease Suggested in Direct Injection Vaccine Treatment of Pancreatic Cancer. Research from Rutgers Cancer Institute of New Jersey to be presented at the Pancreatic Cancer-focused meeting held by AACR in New Orleans.

May 21st 2014

Lung Cancer Screening could Cost Medicare Billions

A new study estimates that it would cost Medicare about $2 billion a year to screen certain current and former heavy smokers for lung cancer.

May 21st 2014

Cost Prevents Approval of Revlimid in the UK...Again

NICE rejected Celgene's Revlimid again for treating patients with myelodysplastic syndrome, quoting concerns with cost-effectiveness of the drug.

May 21st 2014

Clovis Oncology's Treatment for EGFR-mutant (T790M) NSCLC Patients Receives Breakthrough Designation

CO-1686 was assigned breakthrough designation by the FDA as monotherapy for the treatment of EGFR-mutant NSCLC patients.

May 20th 2014

Myriad's Prolaris Diagnostic Kit Holds Value in Prostate Cancer Prognosis

Results presented at the 2014 American Urological Association (AUA) meeting in Florida revealed that Myriad's prostate cancer diagnostic test could predict mortality risk in prostate cancer.

May 20th 2014

Geneticists on Both Coasts Issue 'Call to Action' On Need to Share DNA Data

In the new issue of Evidence-Based Oncology, Ellen T. Matloff, MS, CGC, and Rachel E. Barnett, MS, CGC, of the Yale Cancer Center and Robert Nussbaum, MD, of UC San Francisco write that efforts by some genetic testing laboratories to grab market share in the lucrative BRCA testing market may put patients at risk, while violating ethical standards issued by the American Medical Association.

May 20th 2014

The Role of Bioinformatics in Diabetes Drug Development-and Precision Medicine

Surabhi Dangi-Garimella, PhD

May 20th 2014

Encouraging Results With Radioimmunotherapy and Gemcitabine Treatment in Metastatic PDAC

Combining a novel radioimmunotherapy treatment with gemcitabine presented encouraging results in PDAC patients who had undergone metastasis. The data was presented at a AACR special conference currently being held in New Orleans.

...

161 162 163 164 165 166 167 168 169

...

186 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions